Kura Oncology to Participate in Three Upcoming Investor Conferences
04 nov. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Third Quarter 2020 Financial Results
29 oct. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Reports Preclinical Results Showing Antitumor Activity of Tipifarnib in Combination with PI3Kα Inhibitor in Head and Neck Squamous Cell Carcinoma
26 oct. 2020 07h30 HE
|
Kura Oncology, Inc.
– Preclinical data support potential to expand therapeutic utility of tipifarnib to HRAS/PI3K dependent tumors representing up to 50% of HNSCC – – Company plans to conduct a Phase 1/2...
Kura Oncology Announces Preliminary Data for Menin Inhibitor KO-539 Accepted for Oral Presentation at ASH
07 oct. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 07, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Participate in Two Upcoming Investor Conferences
08 sept. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Appoints Dr. Stephen Dale as Chief Medical Officer
25 août 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology Reports Second Quarter 2020 Financial Results
06 août 2020 16h05 HE
|
Kura Oncology, Inc.
– Anticipate preliminary data presentation of menin inhibitor program, KO-539, at ASH – – Continued progress in registration-directed trial of tipifarnib in HRAS mutant HNSCC – – Opportunity to...
Kura Oncology to Present at Wedbush PacGrow Healthcare Virtual Conference
04 août 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Report Second Quarter 2020 Financial Results
30 juil. 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, July 30, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company focused on the development of precision medicines for the treatment of...
Kura Oncology to Participate in JMP Securities Hematology & Oncology Forum
11 juin 2020 07h30 HE
|
Kura Oncology, Inc.
SAN DIEGO, June 11, 2020 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...